Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2000 | 1 |
2008 | 1 |
2018 | 2 |
2019 | 2 |
2023 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy.
Front Immunol. 2023 May 26;14:1160116. doi: 10.3389/fimmu.2023.1160116. eCollection 2023.
Front Immunol. 2023.
PMID: 37304285
Free PMC article.
HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.
Richards DM, Marschall V, Billian-Frey K, Heinonen K, Merz C, Redondo Müller M, Sefrin JP, Schröder M, Sykora J, Fricke H, Hill O, Gieffers C, Thiemann M.
Richards DM, et al. Among authors: redondo muller m.
J Immunother Cancer. 2019 Jul 19;7(1):191. doi: 10.1186/s40425-019-0671-4.
J Immunother Cancer. 2019.
PMID: 31324216
Free PMC article.
Item in Clipboard
Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity.
Bartz R, Fukuchi K, Ohtsuka T, Lange T, Gruner K, Watanabe I, Hayashi S, Oda Y, Kawaida R, Komori H, Kashimoto Y, Wirtz P, Mayer JA, Redondo-Müller M, Saito S, Takahashi M, Hanzawa H, Imai E, Martinez A, Hanai M, Häussinger D, Chapman RW, Agatsuma T, Bange J, Abraham R.
Bartz R, et al. Among authors: redondo muller m.
Mol Cancer Ther. 2019 Oct;18(10):1832-1843. doi: 10.1158/1535-7163.MCT-18-0048. Epub 2019 Jul 26.
Mol Cancer Ther. 2019.
PMID: 31350344
Item in Clipboard
A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity.
Thiemann M, Richards DM, Heinonen K, Kluge M, Marschall V, Merz C, Redondo Müller M, Schnyder T, Sefrin JP, Sykora J, Fricke H, Gieffers C, Hill O.
Thiemann M, et al. Among authors: redondo muller m.
Front Oncol. 2018 Sep 19;8:387. doi: 10.3389/fonc.2018.00387. eCollection 2018.
Front Oncol. 2018.
PMID: 30298117
Free PMC article.
Item in Clipboard
The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.
Merz C, Sykora J, Marschall V, Richards DM, Heinonen K, Redondo Müller M, Thiemann M, Schnyder T, Fricke H, Hill O, Gieffers C.
Merz C, et al. Among authors: redondo muller m.
J Immunother. 2018 Nov/Dec;41(9):385-398. doi: 10.1097/CJI.0000000000000246.
J Immunother. 2018.
PMID: 30273198
Item in Clipboard
Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor.
Redondo-Müller MA, Stevanovic-Walker M, Barker S, Puddefoot JR, Vinson GP.
Redondo-Müller MA, et al.
Endocr Relat Cancer. 2008 Mar;15(1):277-88. doi: 10.1677/ERC-07-0068.
Endocr Relat Cancer. 2008.
PMID: 18310294
Item in Clipboard
The prevention and treatment of vascular graft infection with a Triclosan (Irgasan)-bonded Dacron graft: an experimental study in the pig.
Hernandez-Richter T, Schardey HM, Löhlein F, Heiss MM, Redondo-Müller M, Hammer C, Schildberg FW.
Hernandez-Richter T, et al. Among authors: redondo muller m.
Eur J Vasc Endovasc Surg. 2000 Nov;20(5):413-8. doi: 10.1053/ejvs.2000.1199.
Eur J Vasc Endovasc Surg. 2000.
PMID: 11112458
Free article.
Item in Clipboard
Cite
Cite